Marc Feinberg, MD
Neurology · Boca Raton, FLNPI 1255422127
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (38.8%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 58 manufacturers, the largest accounting for just 17.4%.
Across 620 payments — averaging $48.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acadia Pharmaceuticals Inc$5K
- Johnson & Johnson$5K
- AbbVie$4K
- Catalyst Pharmaceuticals, Inc.$2K
- Eisai Inc.$2K
- Novartis$1K
- plus $11K from 52 others
Across 280 payments — averaging $11,735 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$830K
- Janssen Research & Development, LLC$613K
- E.r. Squibb & Sons, L.L.C.$412K
- Novartis$331K
- Argenx US, Inc.$253K
- UCB SA$208K
- plus $639K from 17 others
What the payments were for
- Consulting fees$11,55139%
- Speaking & faculty fees$5,61119%
- Travel & lodging$1,5535%
- Food & beverage$11,05237%
- Education$280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$29,796 in reported general payments places this provider in the 85th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 22 | $150,587 |
| MayzentSiponimod | 13 | $122,346 |
| Kesimpta PenOfatumumab | 12 | $101,916 |
| IngrezzaValbenazine Tosylate | 12 | $101,612 |
| Emgality PenGalcanezumab-Gnlm | 89 | $77,945 |
| NuplazidPimavanserin Tartrate | 16 | $77,570 |
| CopaxoneGlatiramer Acetate | 13 | $74,599 |
| RytaryCarbidopa/Levodopa | 51 | $49,968 |
| QuliptaAtogepant | 16 | $32,695 |
| NamzaricMemantine Hcl/Donepezil Hcl | 23 | $26,508 |
| UbrelvyUbrogepant | 26 | $26,478 |
| XcopriCenobamate | 11 | $20,234 |
| Rivastigmine | 93 | $15,457 |
| Lacosamide | 85 | $10,860 |
| Memantine Hcl | 311 | $8,938 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCGamunex-C | $56 | $150,58722 claims |
| NovartisMayzent | $1,364 | $122,34613 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $133 | $101,61212 claims |
| AbbVieQulipta, Namzaric, Ubrelvy | $4,190 | $85,68165 claims |
| Acadia Pharmaceuticals IncNuplazid | $5,180 | $77,57016 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $284 | $74,59913 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $76 | $52,94679 claims |
| SK Life Science, Inc.Xcopri | $28 | $20,23411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,434 neurology providers in Florida.
Other neurology in Boca Raton
- Stuart IsaacsonBoca Raton$3.9M
- Brian SteingoBoca Raton$792K
- Richard IsaacsonBoca Raton$127K
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
- David RoseTampa$1.4M
- Matthew BakerNaples$1.4M
- Donald NegroskiSarasota$1.4M
- Mark CascioneTampa$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.